Medpace Holdings (MEDP) Stock Overview
Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MEDP Community Fair Values
Create NarrativeSee what 75 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Medpace Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$428.03 |
| 52 Week High | US$628.92 |
| 52 Week Low | US$250.05 |
| Beta | 1.4 |
| 1 Month Change | -29.93% |
| 3 Month Change | -26.93% |
| 1 Year Change | 25.83% |
| 3 Year Change | 107.32% |
| 5 Year Change | 168.53% |
| Change since IPO | 1,426.50% |
Recent News & Updates
Medpace Holdings, Inc. (NASDAQ:MEDP) Just Reported, And Analysts Assigned A US$491 Price Target
Feb 13
Medpace Holdings: Great Quarter, Stale Backlog, Full Valuation
Feb 10Recent updates
Medpace Holdings, Inc. (NASDAQ:MEDP) Just Reported, And Analysts Assigned A US$491 Price Target
Feb 13Medpace Holdings: Great Quarter, Stale Backlog, Full Valuation
Feb 10Earnings Not Telling The Story For Medpace Holdings, Inc. (NASDAQ:MEDP) After Shares Rise 34%
Aug 11Medpace Holdings, Inc. Beat Revenue Forecasts By 12%: Here's What Analysts Are Forecasting Next
Jul 24Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Jul 01Is Medpace Holdings, Inc. (NASDAQ:MEDP) Trading At A 48% Discount?
Jun 12Investor Optimism Abounds Medpace Holdings, Inc. (NASDAQ:MEDP) But Growth Is Lacking
May 08Medpace Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 23Is Medpace Holdings, Inc. (NASDAQ:MEDP) Potentially Undervalued?
Mar 24Medpace: Impressive Revenue Growth, High ROE Values, And High Growth Potential
Feb 06Medpace: Buy The Short-Term Pain For Long-Term Gains
Oct 26Why Medpace Holdings Is A 'Better Mousetrap'
Oct 16
Temporary Setbacks Poised For A Swift Recovery And Strong Future Revenue Growth
Elevated project cancellations pose only a temporary risk, with potential for quick revenue and net new business awards recovery.Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity
Aug 20Medpace: Clear Winner If China Blockade Succeeds
Jun 04Medpace: Exceptional Performance, Almost Fully Priced In
Mar 11Shareholder Returns
| MEDP | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -21.0% | -6.9% | -1.3% |
| 1Y | 25.8% | -5.7% | 10.9% |
Return vs Industry: MEDP exceeded the US Life Sciences industry which returned -5.7% over the past year.
Return vs Market: MEDP exceeded the US Market which returned 10.9% over the past year.
Price Volatility
| MEDP volatility | |
|---|---|
| MEDP Average Weekly Movement | 6.2% |
| Life Sciences Industry Average Movement | 7.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MEDP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MEDP's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 6,200 | August Troendle | www.medpace.com |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Medpace Holdings, Inc. Fundamentals Summary
| MEDP fundamental statistics | |
|---|---|
| Market cap | US$12.15b |
| Earnings (TTM) | US$451.12m |
| Revenue (TTM) | US$2.53b |
Is MEDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDP income statement (TTM) | |
|---|---|
| Revenue | US$2.53b |
| Cost of Revenue | US$732.13m |
| Gross Profit | US$1.80b |
| Other Expenses | US$1.35b |
| Earnings | US$451.12m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.90 |
| Gross Margin | 71.06% |
| Net Profit Margin | 17.83% |
| Debt/Equity Ratio | 0% |
How did MEDP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/15 09:39 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medpace Holdings, Inc. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |